Decline Seen in Total Opioid MME Per Capita in Last Decade
Greatest decline in MME volume per capita seen among persons aged 46 to 55 years and in metropolitan counties
Three Days of Remdesivir Cuts Risk for Severe COVID-19 in Outpatients
Three-day course of treatment results in reduced risk for hospitalization or death compared with placebo
Hyaluronic Acid Injection Use Increased for Knee Osteoarthritis in Seniors
Significant increase in utilization and associated costs seen among physicians' assistants and nurse practitioners
Efficacy of Bamlanivimab for COVID-19 May Vary With Antibody Status
Further study needed to determine whether bamlanivimab could benefit patients who are negative for endogenous neutralizing antibodies
Physician’s Briefing Weekly Coronavirus Roundup
Race/Ethnicity-Linked Differences Seen in Type 1 Diabetes Management
Insulin pump use higher among White versus Black and other Medicare beneficiaries
FDA Gives OK to Merck Antiviral At-Home COVID-19 Pill
Molnupiravir cut the risk for hospitalization and death in high-risk patients by 30 percent
FDA Approves New Drug to Help Control Severe Asthma
Tezspire is unique in that it only targets thymic stromal lymphopoietin, the molecule involved in airway inflammation
mRNA COVID-19 Vaccine Less Protective in Elderly With Comorbidity
At ≥7 days after second dose, effectiveness of mRNA COVID-19 vaccine was 69 percent against infection, 86 percent against related death
13 Million Adults Delaying or Skipping Meds Due to Costs
Drug unaffordability is an issue regardless of insurance status and across private, public payers
